2. Academic Validation
  3. The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors

The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors

  • Bioorg Med Chem Lett. 2020 Sep 15;30(18):127412. doi: 10.1016/j.bmcl.2020.127412.
Piotr Raubo 1,  Richard Evans 2,  Paul Willis 2
Affiliations

Affiliations

  • 1 Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK; AstraZeneca R&D Charnwood, Loughborough, UK. Electronic address: piotr.raubo@astrazeneca.com.
  • 2 AstraZeneca R&D Charnwood, Loughborough, UK.
PMID: 32717614 DOI: 10.1016/j.bmcl.2020.127412
Abstract

The discovery and optimisation of a novel series of potent and selective p38α inhibitors is described. Evaluating the structure-activity relationship of an aminoalkyl substituent at the 3 position of the 2(1H)-pyrazinone core, p38α potency was increased 20000-fold. The most advanced compound (25) demonstrated excellent in vivo properties suitable for an inhaled route of administration.

Keywords

AZD6703; AZD7624; COPD; Inflammation; Kinases; P38α.

Figures
Products